Asymmetrical Dimethylarginine Levels in Hepatitis B Virus-Positive Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: High asymmetrical dimethylarginine (ADMA) levels have been associated with endothelial dysfunction and contribute to the development of several diseases. However, data on the relationship between hepatitis B virus (HBV) and ADMA are limited. The aim of our study was to explore the relationship between ADMA and HBV by comparing the ADMA levels in patients with chronic active hepatitis B (CHB), inactive HBV carriers (carriers), and healthy volunteers (controls). Methods: The participants were divided into three groups: 90 patients with CHB, 90 HBV carriers, and 90 controls. Serum ADMA levels were quantified using an ELISA kit (Cusabio, Wuhan, China). The data were analyzed using an ANOVA or the Kruskal-Wallis test as appropriate, with P<0.05 considered significant. Results: Serum ADMA levels were significantly higher in patients with CHB (228.35±91.10 ng/mL) than in HBV carriers (207.80±75.80 ng/mL) and controls (207.61±89.10 ng/mL) (P=0.049). The clinical scores of the patients were positively correlated with ADMA levels. Conclusions: The elevated serum ADMA levels in patients with CHB confirm that HBV plays a role in vasculitis. Further investigation of the mechanisms contributing to the high levels of ADMA in CHB may contribute toward development of new treatment modalities
Abstract
Background: High asymmetrical dimethylarginine (ADMA) levels have been associated with endothelial dysfunction and contribute to the development of several diseases. However, data on the relationship between hepatitis B virus (HBV) and ADMA are limited. The aim of our study was to explore the relationship between ADMA and HBV by comparing the ADMA levels in patients with chronic active hepatitis B (CHB), inactive HBV carriers (carriers), and healthy volunteers (controls). Methods: The participants were divided into three groups: 90 patients with CHB, 90 HBV carriers, and 90 controls. Serum ADMA levels were quantified using an ELISA kit (Cusabio, Wuhan, China). The data were analyzed using an ANOVA or the Kruskal-Wallis test as appropriate, with P<0.05 considered significant. Results: Serum ADMA levels were significantly higher in patients with CHB (228.35±91.10 ng/mL) than in HBV carriers (207.80±75.80 ng/mL) and controls (207.61±89.10 ng/mL) (P=0.049). The clinical scores of the patients were positively correlated with ADMA levels. Conclusions: The elevated serum ADMA levels in patients with CHB confirm that HBV plays a role in vasculitis. Further investigation of the mechanisms contributing to the high levels of ADMA in CHB may contribute toward development of new treatment modalities
참고문헌 (26)
- Aldamiz-Echevarria L, "Asymmetric dimethylarginine, endothelial dysfunction and renal disease", Int J Mol Sci, 13, pp.11288~11311 (2012)[DOI]
- Liu X, "Effect of asymmetric dimethlarginine (ADMA) on heart failure development", Nitric Oxide, 54, pp.73~81 (2016)[DOI]
- Tain YL, "Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA)", Toxins (Basel), 9, pp.E92~ (2017)[DOI]
- McCarty MF, "Asymmetric dimethylarginine is a well-established mediating risk factor for cardiovascular morbidity and mortality-should patients with elevated levels be supplemented with citrulline", Healthcare (Basel), 4, pp.E40~ (2016)[DOI]
- Erbil MK, "Metabolism of asymmetric dimethylarginine and its clinical significance", Turk J Bioch, 37, pp.99~105 (2012)[DOI]
- El Dayem SM, "Asymmetric dimethyl L-arginine, nitric oxide and cardiovacular disease in adolescent type 1 diabetics", J Pediatr Endocrinol Metab, 27, pp.437~444 (2014)
- Taskiran B, "Effect of exercise on ADMA level in type 2 diabetes mellitus", Balkan Med J, 29, pp.62~67 (2012)[DOI]
- Sitar ME, "Asymmetric dimethylarginine and its relation as a biomarker in nephrologic diseases", Biomark Insights, 11, pp.131~137 (2016)
- Ittermann T, "L-Arginine derivatives are associated with the hyperthyroid state in the general population", Thyroid, 26, pp.212~218 (2016)[DOI]
- Aydemir O, "Asymmetric dimethylarginine and L-arginine levels in neonatal sepsis and septic shock", J Matern Fetal Neonatal Med, 28, pp.977~982 (2015)[DOI]
- Ferrigno A, "Liver plays a central role in asymmetric dimethylarginine-mediated organ injury", World J Gastroenterol, 21, pp.5131~5137 (2015)[DOI]
- Mengeloglu Z, "High asymmetric dimethylarginine (ADMA) levels in patients with brucellosis", Inflammation, 37, pp.127~131 (2014)[DOI]
- Baranyi A, "Asymmetric dimethylarginine responses during interferon-<TEX>$\alpha$<", TEX>- induced depression in patients with chronic hepatitis C infection, 2014, pp.76, 197~207
- Hu J, "Complete and incomplete hepatitis B virus particles: formation, function, and application", Viruses, 9, pp.56~ (2017)[DOI]
- Sandhu P, "Hepatitis B virus immunopathology, model systems, and current therapies", Front Immunol, 8, pp.436~ (2017)
- An J, "Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial", BMC Gastroenterol, 17, pp.15~ (2017)[DOI]
- Joshi U, "Hepatitis B virus induced cytoplasmic antineutrophil cytoplasmic antibody-mediated vasculitis causing subarachnoid hemorrhage acute transverse myelitis, and nephropathy: a case report", J Med Case Rep, 11, pp.91~ (2017)[DOI]
- Ishak K, "Histological grading and staging of chronic hepatitis", J Hepatol, 22, pp.696~699 (1995)[DOI]
- Lluch P, "Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis", World J Gastroenterol, 21, pp.9466~9475 (2015)[DOI]
- Nickovic V, "Diagnostical significance of dimethylarginine in the development of hepatorenal syndrome in patients with alcoholic liver cirrhosis", Vojnosanit Pregl, 69, pp.686~691 (2012)[DOI]
- Brenner T, "L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure", Mediators Inflamm, 2012, pp.210454~ (2012)
- Mookerjee RP, "Increasing dimethylarginine levels are associated with adverse clinical outcome in several alcoholic hepatitis", Hepatology, 45, pp.62~71 (2007)[DOI]
- Beltran LM, "Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection", PLoS One, 9, pp.e90541~ (2014)[DOI]
- Kuller LH, "Inflammatory and coagulation biomarkers and mortality in patients with HIV infection", PLoS Med, 5, pp.e203~ (2008)[DOI]
- Kristoffersen US, "Reduction in circulating markers of endothelial dsyfunction in HIV-infected patients during antiretroviral therapy", HIV Med, 10, pp.79~87 (2009)[DOI]
- Lluch P, "Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C", Scand J Gastroenterol, 44, pp.224~228 (2009)[DOI]